Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.44 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6214102 | 0.83 | ALDH1A1 (0.46) | LMNATP53PDE4BPDE7AALDH1A1 | |
| SCHEMBL6217688 | 0.81 | LMNA (0.66) | LMNATP53ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL6217686 | 0.81 | LMNA (0.66) | LMNATP53ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL7518263 | 0.81 | LMNA (0.47) | LMNATP53PDE4BPDE7AALDH1A1 | |
| SCHEMBL6224299 | 0.81 | MEN1 (0.52) | LMNATP53POLBMEN1KMT2A | |
| SCHEMBL6222276 | 0.81 | LMNA (0.54) | LMNATP53KMT2A | |
| SCHEMBL6222277 | 0.81 | LMNA (0.54) | LMNATP53KMT2A | |
| SCHEMBL7512391 | 0.81 | KMT2A (0.57) | LMNATP53ALDH1A1CYP2D6CYP2C19 | |
| SCHEMBL7512385 | 0.81 | KMT2A (0.57) | LMNATP53ALDH1A1CYP2D6CYP2C19 | |
| SCHEMBL7509789 | 0.80 | TP53 (0.51) | LMNATP53SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0884310-B1 | Quinazolin-4-one ampa antagonists | PFIZER PROD INC (US) | 2005-09-07 | — | — | EP | disclosed |
| US-6921764-B2 | Thieno-pyrimidin-4-one AMPA antagonists | PFIZER INC. (US) | 2005-07-26 | — | — | US | disclosed |
| US-20040049039-A1 | Quinazolin-4-one ampa antagonists | PFIZER INC | 2004-03-11 | — | — | US | disclosed |
| US-6627755-B1 | Neurodegenerative, psychological, and nervous system disorder; drug abuse, alcoholism | PFIZER INC | 2003-09-30 | — | — | US | disclosed |
| EP-0884310-A1 | Quinazolin-4-one ampa antagonists | Pfizer Products Inc. (US) | 1998-12-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040049039-A1 | Quinazolin-4-one ampa antagonists | GRIN1, GRIK1, GRIN3A | LMNA 4699/4885TP53 4570/4885PDE4B 976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.